This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


 Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Nov. 7, 2013


Advertisement

Advertisement
 

Advertisement


SOCIETY NEWS


President's Blog: Light Up the Darkness
AST
In his latest blog post, AST President, Dr. Dan Salomon, discusses the first event of the new AST Power2Save  initiative. On Nov. 1, more than 2,200 people joined the AST at a concert in Madison, Wisc., to see Scott MacIntyre, Joel Crouse, and The Band Perry perform, as well as to hear inspiring stories about the power of organ donation and the miracle of transplantation. Dr. Salomon described the event as "an amazing night of rocking country music to raise money and awareness for the AST's goals of advancing organ donation, public advocacy and research." Read the full blog post here .
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


T3: Register now for IPITA conference summary webinar on Nov. 19
AST
Webinars for the Timely Topics in Transplantation series are broadcast live on a Tuesday at 2 p.m. EST.  Click here to register, members just use your AST username and password during registration to waive the fee!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


It's time to renew your AST membership!
AST
To continue receiving all of the benefits AST membership has to offer through 2014, please login to the AST website now to pay your dues. If you have forgotten your login credentials, simply click the info@myAST.org with any questions.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


Stay warm with AST apparel!
AST
Starting to feel that November chill? Warm up with an AST fleece jacket or pullover. Starting at $35 and in sizes up to 3XL, we’ve got you covered! Shop the AST Store here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


AASLD Report


Many liver transplant patients unable to afford meds
Medscape (login required)
One in 6 liver transplant recipients say they make trade-offs between buying food and their medication or they space out doses because they cannot afford them and try to make them last longer, a new study finds. "Transplantations are not immune from these cost barriers," Marina Serper, MD, a transplant hepatology fellow at the University of Pennsylvania in Philadelphia, told Medscape Medical News. "Financial situations change. These things are important in the chronic disease population, and they're important in the transplant population as well."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


New HCV drugs offer hope after transplant
MedPage Today
The advent of new all-oral regimens for hepatitis C (HCV) offers hope to patients who have undergone liver transplant and had the disease recur, a researcher said here. Patients with hepatitis C who get a new liver universally have a recurrence of the disease in the new organ, according to Dr. Michael Charlton of the Mayo Clinic in Rochester.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




First study of its kind shows that all-oral treatment regimen prevents hepatitis C recurrence in liver transplant recipients who received allografts
Newswire via Reuters
For the first time, researchers have been able to prevent the recurrence of hepatitis C virus (HCV) infection in a large proportion of patients (64 percent, n=25/39) who undergo liver transplantation for cirrhosis complicated by hepatocellular carcinoma (HCC). This success was achieved with an interferon-free treatment regimen containing the oral antivirals sofosbuvir, an investigational agent, and ribavirin.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement


Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit astellas.us
Advertisement
University of Vermont Transplant Nephrologist

The University of Vermont/Fletcher Allen Health Care is seeking applications for a senior faculty member to join the Division of Nephrology. The candidate should be UNOS certified in kidney and pancreas transplants, experienced in educating nephrology fellows, growing transplant programs, and providing administrative leadership. Apply Here
Amnis
The FlowSight offers high performance in a small package. Its innovative design increases signal and minimizes noise to provide unmatched fluorescence sensitivity. Twelve standard detection channels simultaneously produce brightfield, darkfield and up to ten channels of fluorescence imagery of every cell. More info


TRANSPLANT NEWS


Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients
Transplantation (login required)
Recipients of incompatible allografts are at increased risk of graft loss. It has been hypothesized that analysis of sequential biopsies from these grafts could define progression of graft lesions and identify features predictive of progression.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


AASLD - COSMOS study with Simeprevir and Sofosbuvir in cirrhotic and non-cirrhotic HCV genotype 1 patients
HCV New Drug Research
Medivir AB recently announced data from the interferon-free COSMOS study demonstrating safety and efficacy of the investigational protease inhibitor simeprevir (TMC435) in combination with the investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease was presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C. during the late-breaking oral session on Monday, Nov. 4.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Diagnose faster, when it matters most.
For nearly 30 years, physicians have trusted Viracor-IBT Laboratories to provide accelerated results, specialized expertise and exceptional service in transplant testing. Learn more at www.viracoribt.com.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


Study: Vitamin D deficiency and mortality in patients receiving dialysis
Journal of Renal Nutrition (login required)
Although several studies have shown poorer survival among individuals with 25-hydroxy (OH) vitamin D deficiency, data on patients receiving dialysis are limited. Using data from the Comprehensive Dialysis Study (CDS), researchers tested the hypothesis that patients new to dialysis with low serum concentrations of 25-OH vitamin D would experience higher mortality and hospitalizations.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Lung transplant 'patient 45' remembered 30 years on
CBC News
Lung transplant recipients, doctors and nurses are celebrating the 30th anniversary of the world's first successful lung transplant in Toronto. In 1983, Tom Hall was the 45th patient in the world to receive a single lung at what was then Toronto General Hospital. Tom Hall visits Paris, five years after his lung transplant. Before his successful operation, transplant recipients had not lived beyond a few days or weeks. (Courtesy University Health Network) Hall lived more than six years — the first to survive for more than days or weeks after receiving the organ.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Looking to share your expertise?
MultiBriefs
In an effort to enhance the overall content of AST eNews, we’d like to include peer-written articles in future editions. As a member of AST, your knowledge of the industry lends itself to unprecedented expertise. And we're hoping you'll share this expertise with your peers through well-written commentary. Because of the digital format, there’s no word or graphical limit and our group of talented editors can help with final edits. If you’re interested in participating, please contact Ronnie Richard to discuss logistics.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




Birmingham research tackles liver transplant failure
Health Canal
The re-infection of transplanted livers with hepatitis C virus (HCV) — which can irreparably damage the new organ — could be halted by administering a drug which blocks the virus entering the liver, research from the University of Birmingham being presented at the Liver Meeting demonstrates.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Study: Kidney transplant rejection drugs tied to pregnancy risks (HealthDay News via U.S. News and World Report)
Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection (Transplantation)
Transplant Surgeons: Meet your ABS MOC requirements through the AJT (American Journal of Transplantation (login required))
Research: Old cancer drug may help prevent rejection after transplantation (By Joy Burgess)
Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin (Transplantation)

Don't be left behind. Click here to see what else you missed.


Does liver ischemic preconditioning in brain death donors induce kidney preconditioning? A retrospective analysis
NCBI
It is unclear whether ischemic preconditioning (IPC) of solid organs induces remote IPC (RIPC) in donors after brain death (DBD). In a recent study, outcomes in kidney recipients from 163 DBD in two randomized trials of liver IPC (5 min=62 and 10 min=101) were obtained retrospectively from the Scientific Registry of Transplant Recipients. Controls were kidney recipients from donors without IPC.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Nov. 1, 2013
Oct. 25, 2013
Oct. 19, 2013
Oct. 11, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063